venous thrombosis - antithrombotics - all type of patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>venous thrombosis</strong> - antithrombotics </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> Bratt et al , 1985 </a> <br> </td> <td> Dalteparin Intravenousv (ajusted) for >=5 Days, 120 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx1.7-3.5 </td> <td> </td> <td> follow-up 23 Months (mean)<br> n=25/29<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Holm et al , 1986 </a> <br> </td> <td> Dalteparin Subcutaneous twice daily ajusted for 7 Days, 57-107 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin subcutaneous twice daily 16000-30000 U </td> <td> </td> <td> follow-up Hospital Stay<br> n=29/27<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Faivre et al , 1988 </a> <br> </td> <td> Minoctoparine (CY222) Subcutaneous twice daily for 10 Days,155 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin subcutaneous twice daily APPTx2-3 </td> <td> </td> <td> follow-up 10 Days<br> n=33/37<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bratt et al, 1990 </a> <br> </td> <td> Dalteparin Subcutaneous twice daily ajusted for >= 5 Days, 120 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx2-4 </td> <td> </td> <td> follow-up Hospital stay<br> n=60/60<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Collaborative European Multicentre, 1991 </a> <br> </td> <td> Nadroparin Subcutaneous twice daily for 10 Days, 90 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx1.5-2 </td> <td> </td> <td> follow-up 12 Weeks<br> n=70/66<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Prandoni et al , 1992 </a> <br> </td> <td> Nadroparin Subcutaneous twice daily for >=0 Days, 90 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx1.5-2 </td> <td> </td> <td> follow-up 6 Months<br> n=85/85<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lopaciuk et al , 1992 </a> <br> </td> <td> Nadroparin Subcutaneous twice daily for 10 Days, 92 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin subcutaneous twice daily APPTx1.5-2.5 </td> <td> </td> <td> follow-up 3 Months<br> n=74/75<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hull et al , 1992 </a> <br> </td> <td> Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx2-3 </td> <td> </td> <td> follow-up 3 Months<br> n=213/219<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Simonneau et al , 1993 </a> <br> </td> <td> Enoxaparin Subcutaneous twice daily for 0 Days, 100 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx1.5-2.5 </td> <td> </td> <td> follow-up 3 Months<br> n=67/67<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lindmarker et al , 1993 </a> <br> </td> <td> Dalteparin Subcutaneous once daily for >= 5 Days, 200 U/kg BID<br>  <i>versus</i> <br> unfractionated heparin intravenous APPTx1.5-3 </td> <td> </td> <td> follow-up 6 Months<br> n=101/103<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Charbonnier, 1998 </a> <br> </td> <td> Once daily nadroparin 20,500 (AXa IU/ml)continued for at least 5 days<br>  <i>versus</i> <br> twice daily nadroparin 10,250 (AXa IU/ml)continued for at least 5 days </td> <td> patients with acute symptomatic proximal DVT in popliteal vein or above documented by venography </td> <td> follow-up <br> n=316/335<br> Parallel groups<br> double blind <br> Europe </td> </tr> <tr> <td> <a href="index.html"> Holmstr�m, 1992 </a> <br> </td> <td> once daily dalteparin 200 U (anti-FXa)/kg for at least 5 days<br>  <i>versus</i> <br> twice daily dalteparin 100 U (anti-FXa)/kg for at least 5 days </td> <td> Patients with a first occurence of DVT in the lower limb, confirmed with phlebographytio </td> <td> follow-up <br> n=50/51<br> Parallel groups<br> open <br> Sweden </td> </tr> <tr> <td> <a href="index.html"> Merli, 2001 </a> <br> </td> <td> enoxaparin 1.5 mg/kg body weight once daily<br>  <i>versus</i> <br> S.c. enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily </td> <td> patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE) </td> <td> follow-up <br> n=298/312<br> Parallel groups<br> double blind <br> Europe, United States of America and Australia, image/pj </td> </tr> <tr> <td> <a href="index.html"> Partsch, 1996 </a> <br> </td> <td> Fragmin administered 200 IU/kg once daily for at least 7 days<br>  <i>versus</i> <br> Fragmin 100 IU/kg twice daily for at least 7 days </td> <td> patients presented with DVT extending into the iliofemoral segment diagnosed by duplex ultrasonographyA </td> <td> follow-up <br> n=76/64<br> Parallel groups<br> NA <br> Austria </td> </tr> <tr> <td> <a href="index.html"> Siegbahn, 1989 </a> <br> </td> <td> Once daily logiparin 150 XaI U/kgp, imag<br>  <i>versus</i> <br> twice daily logiparin 75 XaI U/kg </td> <td> patients with a venographically confirmed episode of DVT </td> <td> follow-up <br> n=10/10<br> Parallel groups<br> single blind <br> Sweden and Denmark </td> </tr> <tr> <td> <a href="index.html"> Levine, 1995 </a> <br> </td> <td> continuation for 2 months of warfarin adjusted INR value of 2.0 to 3.0<br>  <i>versus</i> <br> Discontinue oral anticoagulant therapy (after 1 months) </td> <td> </td> <td> follow-up 11 months after randomization.<br> n=-9/-9<br> Parallel groups<br> double blind <br> Canada, Italy </td> </tr> <tr> <td> <a href="index.html"> Schulman, 1995 </a> <br> </td> <td> 6 months treatment with warfarin or dicoumarol adjusted for a target INR between 2.0 - 2.85<br>  <i>versus</i> <br> 1.5 months warfarin or dicoumarol adjusted for a target INR between 2.0 - 2.85 </td> <td> </td> <td> follow-up Two years after randomization<br> n=-9/-9<br> Parallel groups<br> open <br> Sweden </td> </tr> <tr> <td> <a href="index.html"> Kearon, 1999 </a> <br> </td> <td> Continuation of the oral anticoagulant therapy up to 24 months, warfarin was adjusted to achieve a target INR between 2.0 and 3.0.<br>  <i>versus</i> <br> discontinuation (after 3 months) </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Agnelli, 2001 </a> <br> </td> <td> continuation for 9 additional months; warfarin or acenocoumarol adjusted to achieve a target INR between 2.0 and 3.0<br>  <i>versus</i> <br> discontinuation (after 3 months months) </td> <td> </td> <td> follow-up 33 months<br> n=-9/-9<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> Pinede, 2001 </a> <br> </td> <td> Long course of therapy (6 months for proximal DVT and/or PE; 12 weeks for calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0<br>  <i>versus</i> <br> Short oral anticoagulant course (3 months for proximal DVT and/or PE; 6 weeks for isolated calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0 </td> <td> </td> <td> follow-up 15 months after randomization�<br> n=-9/-9<br> Parallel groups<br> open <br> France </td> </tr> <tr> <td> <a href="index.html"> Agnelli, 2003 </a> <br> </td> <td> continuation for 3 or 9 additionnal months of warfarin or other oral anticoagulant was adjusted to achieve a target INR between 2.0 and 3.0.<br>  <i>versus</i> <br> discontinuation (after 3 months) </td> <td> </td> <td> follow-up 33 months<br> n=-9/-9<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> Kearon, 2004 </a> <br> </td> <td> continuation for 2 additionnal months of warfarin adjusted to achieve a target INR between 2.0 and 3.0.<br>  <i>versus</i> <br> discontinuation (after 1 months) </td> <td> </td> <td> follow-up 11 months (after randomizatio)<br> n=-9/-9<br> Parallel groups<br> double blind <br> Canada, US </td> </tr> <tr> <td> <a href="index.html"> Boccalon, 2000 </a> <br> </td> <td> home treatment with sub-cutaneous injection of LMWH (dalteparin sodium, enoxaparin sodium or nadroparin calciumas chosen by the attending physician) at the recommended dose followed by anticoagulant for 6months<br>  <i>versus</i> <br> Sub-cutaneous injection of LMWH(dalteparin sodium, enoxaparin sodium or nadroparin calcium as chosen by attending physician) at the recommended dose followed by anticoagulant for 6 months initially in hospital for 10 +/- 2 days then at home </td> <td> patienst with confirmed diagnosis (by ultrasonography or venography) of proximal DVT not more than 30 days before enrolment </td> <td> follow-up 6 months<br> n=99/101<br> Parallel groups<br> NA <br> France </td> </tr> <tr> <td> <a href="index.html"> Chong, 2005 </a> <br> </td> <td> once daily sub-cutaneous injection of enoxaparin 1.5mg/kg for a minimum of 5 days plus 10mg of warfarin for 3 months adjusted to achieve INR above 2 and within range accepted by the investigator<br>  <i>versus</i> <br> 5000 IU bolus of unfractionated heparin (UFH) for a minimum of 5 days plus 10mg warfarin started on day 1 of the treatment for 3 months </td> <td> patients with diagnosis of symptomatic lower extrimity DVT (proimal or distal) confirmed by either contrast venography and/or ultrasonography, be suitable for treatment in an outpatient setting </td> <td> follow-up 24 months<br> n=150/148<br> Parallel groups<br> open <br> Australia, New Zealand, Poland, South Africa </td> </tr> <tr> <td> <a href="index.html"> Daskalopoulos, 2005 </a> <br> </td> <td> home treatment with single sub- cutaneous injection of LMWH (tinzaparin sodium) in a weight adjusted dose (175 anti Xa IU/Kg) daily for 6 months<br>  <i>versus</i> <br> Intravenous bolus of 5000IU UFH followed by intrvenous infusion of UFH for 5-7 days. APTT was measured after 4 hours of the initiation of heparin administration and was repeated 6 hours thereafter to reach the therapeutic range (ratio: 1.5-2.5). Oral an </td> <td> patients with acute proximal DVT confirmed by colour duplex UScan not more than 1 week onset </td> <td> follow-up <br> n=55/53<br> Parallel groups<br> open <br> Greece </td> </tr> <tr> <td> <a href="index.html"> Koopman, 1996 </a> <br> </td> <td> home treatment with twice daily injections of nadroparin at a dose adjusted for patient�s weight;<br>  <i>versus</i> <br> UH (APTT adjusted dose, continuous intravenous infusion of 1250 IU per hour after initial intravenous bolus of 5000 IU) in hospital. </td> <td> patients with acute symptomatic proximal DVT proven by venography or duplex scan </td> <td> follow-up 12 weeks<br> n=202/198<br> Parallel groups<br> open <br> The Netherlands, France, Italy, New Zealand Australia </td> </tr> <tr> <td> <a href="index.html"> Levine, 1996 </a> <br> </td> <td> home treatment by Sub-cutaneous enoxaparin 1 mg per kg body weight twice a day for at least 5 days<br>  <i>versus</i> <br> UH (APTT adjusted dose, continuous intravenous infusion of 20,000 IU after initial intravenous bolus of 5000 IU) in hospital for at least 5 days </td> <td> patients with acute proximal DVT proven on venography or duplex scan </td> <td> follow-up 90 days<br> n=247/253<br> Parallel groups<br> open <br> Canada </td> </tr> <tr> <td> <a href="index.html"> Ramacciotti, 2004 </a> <br> </td> <td> home treatment by once daily Subcutaneous injection of enoxaparin at a dose of 1.5 mg/kg for 5-10 days<br>  <i>versus</i> <br> in hospital intravenous bolus injection of 5000 IU of UFH followed by intravenous 500 IU/kg/day adjusted to maintain an aPTT of 1.5-2.5 times the normal value for 5-10 days. </td> <td> patienst with DVT symptoms for greater than or equal to 10 days and proximal lower limb DVT confirmed by duplex ultrasound or venography </td> <td> follow-up <br> n=104/97<br> Parallel groups<br> open <br> Brazil </td> </tr> <tr> <td> <a href="index.html"> Merli (once daily vs UFH), 2001 </a> <br> </td> <td> Initial therapy with enoxaparin 1.5 mg/kg body weight once daily <br>  <i>versus</i> <br> Initial therapy with dose-adjusted intravenous unfractionated heparin </td> <td> patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE) </td> <td> follow-up 3 months<br> n=298/290<br> Parallel groups<br> partialy blinded <br> Europe, United States of America and Australia, image/pj </td> </tr> <tr> <td> <a href="index.html"> Schulman, 1997 </a> <br> </td> <td> indefinite warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85<br>  <i>versus</i> <br> 6 months warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85 </td> <td> </td> <td> follow-up Four years after randomization<br> n=-9/-9<br> Parallel groups<br> open <br> Sweden </td> </tr> <tr> <td> <a href="index.html"> MATISSE, 2004 </a> <br> </td> <td> fondaparinux 7.5 mg subcutaneously once daily for at least 5 days and until vitamin K antagonists induced an INR greater than 2.0.<br>  <i>versus</i> <br> enoxaparin, 1 mg/kg of body weight, subcutaneously twice daily for at least 5 days and until vitamin K antagonists induced an INR greater than 2.0. </td> <td> patients with acute symptomatic deep venous thrombosis </td> <td> follow-up 3 months<br> n=1098/1107<br> Parallel groups<br> double blind <br> international </td> </tr> <tr> <td> <a href="index.html"> THRIVE I, 0 </a> <br> </td> <td> oral ximelagatran (24, 36, 48 or 60 mg twice daily) for 2 weeks<br>  <i>versus</i> <br> dalteparin and warfarin for 2 weeks </td> <td> Patients with acute DVT </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Ott import�, 1998 </a> <br> </td> <td> anticoagulants (s.c. heparin followed by oral warfarin) (duration NA)<br>  <i>versus</i> <br> s.c. saline followed by oral placebo tablets </td> <td> </td> <td> follow-up <br> n=11/12<br> <br> double blind <br> Denmark </td> </tr> <tr> <td> <a href="index.html"> Nielsen import�, 1994 </a> <br> </td> <td> heparin and phenprocoumon for 3 months<br>  <i>versus</i> <br> phenylbutazone </td> <td> </td> <td> follow-up <br> n=48/42<br> <br> open <br> Denmark </td> </tr> <tr> <td> <a href="index.html"> Fiessinger , 2005 </a> <br> </td> <td> ximelagatran 36 mg twice daily<br>  <i>versus</i> <br> subcutaneous enoxaparin, 1 mg/kg twice daily, for 5 to 20 days followed by warfarin adjusted to maintain an international normalized ratio of 2.0 to 3.0. </td> <td> patients with acute deep vein thrombosis </td> <td> follow-up <br> n=-9/-9<br> <br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Krahenbuhl, 1979 </a> <br> </td> <td> subcutaneous sodic heparin 30 000 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 30 000 U daily (mean) </td> <td> </td> <td> follow-up <br> n=23/25<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Bentley, 1980 </a> <br> </td> <td> subcutaneous calcic heparin 37 000 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 36 800 U daily (mean) </td> <td> </td> <td> follow-up <br> n=50/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Andersson, 1982 </a> <br> </td> <td> subcutaneous sodic heparin 36 800 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 33 250 U daily (mean) </td> <td> </td> <td> follow-up <br> n=72/69<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Hull, 1986 </a> <br> </td> <td> subcutaneous sodic heparin 32 300 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 29 700 U daily (mean) </td> <td> </td> <td> follow-up <br> n=57/58<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Doyle, 1987 </a> <br> </td> <td> subcutaneous calcic heparin 29 200 U daily (mean)<br>  <i>versus</i> <br> intravenous calcic heparin 29 600 U daily (mean) </td> <td> </td> <td> follow-up <br> n=51/52<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Walker, 1987 </a> <br> </td> <td> subcutaneous calcic heparin 29 375 U daily (mean)<br>  <i>versus</i> <br> intravenous calcic heparin 24 384 U daily (mean) </td> <td> </td> <td> follow-up <br> n=50/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lopaciuk, 3000 </a> <br> </td> <td> subcutaneous sodic heparin 34 400 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 37 000 U daily (mean) </td> <td> </td> <td> follow-up <br> n=48/46<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pini, 1990 </a> <br> </td> <td> subcutaneous calcic heparin 33 800 U daily (mean)<br>  <i>versus</i> <br> intravenous sodic heparin 31 700 U daily (mean) </td> <td> </td> <td> follow-up <br> n=138/133<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Pini, 1994 </a> <br> </td> <td> UFH, APTT 1.3�1.9 followed by Enoxaparin 4,000 IU qd<br>  <i>versus</i> <br> UFH, APTT 1.3�1.9 followed by Warfarin target INR 2-3.5 </td> <td> patients with objective diagnosis of DVT by Venography (diagnosed by strain-gauge plethysmography plus D-dimer latex assay and confirmed by venography) </td> <td> follow-up 9 mo<br> n=93/94<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Das, 1996 </a> <br> </td> <td> UFH followed by Dalteparin 5,000 IU qd<br>  <i>versus</i> <br> UFH followed by Warfarin target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography </td> <td> follow-up 3 mo<br> n=50/55<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Gonzalez-Fajardo, 1999 </a> <br> </td> <td> LMWH, 4,000 IU bid followed by Enoxaparin 4,000 IU qd<br>  <i>versus</i> <br> UFH followed by Warfarin target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography </td> <td> follow-up 9 mo<br> n=93/92<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lopaciuk, 1999 </a> <br> </td> <td> LMWH, 85 UI/kg bid followed by Nadroparin 85 IU/kg qd<br>  <i>versus</i> <br> LMWH, 85 UI/kg bid followed by Acenocoumarol target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography </td> <td> follow-up 9 mo<br> n=101/101<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Veiga, 2000 </a> <br> </td> <td> UFH, APTT 1.5�2.0d followed by Enoxaparin 4,000 IU qd<br>  <i>versus</i> <br> UFH, APTT 1.5�2.0d followed by Acenocoumarol target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography </td> <td> follow-up 6-9 mo<br> n=50/50<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lopez-Beret, 2001 </a> <br> </td> <td> LMWH, 1,025 IU/10 kg bid followed by Nadroparin 1,025 IU/10 kg bid<br>  <i>versus</i> <br> LMWH, 1,025 IU/10 kg bid followed by Acenocoumarol target INR 2-3 </td> <td> patients with objective diagnosis of DVT by compression ultrasonography </td> <td> follow-up 6-9 mo<br> n=81/77<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Meyer, 2002 </a> <br> </td> <td> LMWH, 1.5 mg/kg qd followed by Enoxaparin 1.5 mg/Kg qd<br>  <i>versus</i> <br> LMWH, 1.5 mg/kg qd followed by Warfarin target INR 2-3 </td> <td> patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography </td> <td> follow-up 3 mo<br> n=71/58<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Hull, 2002 </a> <br> </td> <td> LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd<br>  <i>versus</i> <br> UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography/compression ultrasonography </td> <td> follow-up 9 mo<br> n=369/368<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Deitcher, 2003 </a> <br> </td> <td> LMWH: 1a, 1 mg/kg q12h; 1b, 1 mg/kg qd12h followed by Enoxaparin 1a: 1 mg/kg qd; 1b: 1.5 mg/kg qd<br>  <i>versus</i> <br> LMWH, 1 mg/kg q12h followed by Warfarin target INR 2-3 </td> <td> patients with objective diagnosis of DVT </td> <td> follow-up 6 mo<br> n=51/30<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Kakkar, 2003 </a> <br> </td> <td> LMWH, 115 IU/kg qd followed by Bemiparin 3,500 IU qd<br>  <i>versus</i> <br> A: UFH, 30/40,000IU qd; B: LMWH, 115 IU/kg qd followed by Warfarin target INR 2-3 </td> <td> patients with objective diagnosis of DVT by Venography/compression ultrasonography </td> <td> follow-up 3 mo<br> n=221/103<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lee, 2003 </a> <br> </td> <td> LMWH, 200 IU/kg qd followed by Dalteparin 150 IU/kg qd<br>  <i>versus</i> <br> LMWH, 200 IU/kg qd followed by Warfarin target INR 2-3 </td> <td> patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography </td> <td> follow-up 6 mo<br> n=336/336<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Einstein-DVT Dose-Ranging Study, 2008 </a> <br> </td> <td> rivaroxaban 20, 30, or 40 mg once daily<br>  <i>versus</i> <br> low-molecular-weight heparin followed by vitamin K antagonists </td> <td> patients with deep vein thrombosis </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Botticelli DVT, 2008 </a> <br> NCT00252005 </td> <td> apixaban 5 mg twice-daily, 10 mg twice-daily, or 20 mg once-daily for 84-91 days<br>  <i>versus</i> <br> low molecular weight heparin followed by vitamin K antagonists </td> <td> patients with symptomatic deep vein thrombosis </td> <td> follow-up <br> n=358/118<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Gonz�lez-Fajardo, 2008 </a> <br> </td> <td> long-term anticoagulant treatment with enoxaparin during at least 3 months<br>  <i>versus</i> <br> long-term anticoagulant treatment with coumarin during at least 3 months </td> <td> patients with symptomatic, unilateral, first-episode DVT </td> <td> follow-up 1y, 5y<br> n=85/80<br> Parallel groups<br> open, blind assessment <br> Spain </td> </tr> <tr> <td> <a href="index.html"> VanGogh DVT, 2007 </a> <br> NCT00067093 </td> <td> subcutaneous idraparinux (2.5 mg once weekly)<br>  <i>versus</i> <br> heparin followed by an adjusted-dose vitamin K antagonist </td> <td> patients with deep-vein thrombosis </td> <td> follow-up 3 mo (6 mo)<br> n=1452/1452<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Romera, 2009 </a> <br> </td> <td> tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months<br>  <i>versus</i> <br> acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) </td> <td> patients with symptomatic proximal DVT of the lowerlimbs confirmed by compression duplex ultrasound scan </td> <td> follow-up 12 months<br> n=119/122<br> Parallel groups<br> open <br> Spain </td> </tr> <tr> <td> <a href="index.html"> Einstein-DVT Evaluation, 2010 </a> <br> NCT00440193 </td> <td> rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg daily<br>  <i>versus</i> <br> enoxaparin 1 mg/kg twice daily >=5 days, then warfarin with target INR between 2-3 </td> <td> Patients With Confirmed Acute Symptomatic Deep-Vein Thrombosis without Pulmonary Embolism </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open (assessor-blind) <br> </td> </tr> <tr> <td> <a href="index.html"> RE-COVER, 2009 </a> <br> NCT00291330 </td> <td> dabigatran 150 mg twice daily in a fixed-dose<br>  <i>versus</i> <br> warfarin dose-adjusted to an INR between 2.0 and 3.0 </td> <td> patients with acute venous thromboembolism , treated with low molecular weight or unfractionated heparin for 5 to 11 days </td> <td> follow-up 6 months<br> n=1274/1265<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> VanGogh PE, 2007 </a> <br> NCT00062803 </td> <td> subcutaneous idraparinux (2.5 mg once weekly) <br>  <i>versus</i> <br> heparin followed by an adjusted-dose vitamin K antagonist </td> <td> patients with pulmonary embolism </td> <td> follow-up 3 mo (6 mo)<br> n=1095/1120<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> MATISSE PE, 2003 </a> <br> </td> <td> fondaparinux subcutaneously once daily<br>  <i>versus</i> <br> continuous intravenous infusion of unfractionated heparin </td> <td> patients with acute symptomatic pulmonary embolism </td> <td> follow-up 3 mo<br> n=1103/1110<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Einstein-PE Evaluation, </a> <br> NCT00439777 </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> CV185-056, </a> <br> NCT00643201 </td> <td> apixaban 10 mg twice daily for 7 days then 5 mg, twice daily, 6 months<br>  <i>versus</i> <br> enoxaparin 1mg/kg twice daily until INR>=2 then warfarin for an INR between 2-4, once daikly, 6 months </td> <td> patients with deep vein thrombosis or pulmonary embolism </td> <td> follow-up 6 mo<br> n=4816/0<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> CV185-057, </a> <br> NCT00633893 </td> <td> Extended Treatment with apixaban 5 or 2.5 mg twice daily 12 months<br>  <i>versus</i> <br> placebo </td> <td> patients who have completed their intended treatment for deep vein thrombosis or pulmonary embolism </td> <td> follow-up 12 mo<br> n=2430/0<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>Bratt et al , 1985 : </b> Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner DA comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. <i>Thromb Haemost 1985 Dec 17;54:813-7</i> [PMID 3911482] </p> <p> <b>Faivre et al , 1988 : </b> Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, Toulemonde F, Bassand JP, Maurat JP[A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study] <i>Presse Med 1988 Feb 13;17:197-200</i> [PMID 2965375] </p> <p> <b>Zanghi, 1988 : </b> Zanghi' M, Morici V, Costanzo M, Astuto L, Salanitri GDeep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. <i>J Int Med Res 1988 Nov-Dec;16:474-84</i> [PMID 3069522] </p> <p> <b>Etude Multicentrique , 1989 : </b> [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study] <i>Rev Med Interne 1989 Jul-Aug;10:375-81</i> [PMID 2552552] </p> <p> <b>Albada et al , 1989 : </b> Albada J, Nieuwenhuis HK, Sixma JJTreatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. <i>Circulation 1989 Oct;80:935-40</i> [PMID 2551537] </p> <p> <b>Bratt et al, 1990 : </b> Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner DTwo daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). <i>Thromb Haemost 1990 Dec 28;64:506-10</i> [PMID 1964751] </p> <p> <b>Collaborative European Multicentre, 1991 : </b> A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. <i>Thromb Haemost 1991 Mar 4;65:251-6</i> [PMID 1646490] </p> <p> <b>Prandoni et al , 1992 : </b> Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JWComparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. <i>Lancet 1992 Feb 22;339:441-5</i> [PMID 1346817] </p> <p> <b>Lopaciuk et al , 1992 : </b> Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska ESubcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. <i>Thromb Haemost 1992 Jul 6;68:14-8</i> [PMID 1325076] </p> <p> <b>Hull et al , 1992 : </b> Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HRSubcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. <i>N Engl J Med 1992 Apr 9;326:975-82</i> [PMID 1545850] </p> <p> <b>Simonneau et al , 1993 : </b> Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe SSubcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. <i>Arch Intern Med 1993 Jul 12;153:1541-6</i> [PMID 8391792] </p> <p> <b>Lindmarker et al , 1993 : </b> Ruan C, Gu J, Wang X, Chu X, Pan JApplication of GPIIIa gene Taq I polymorphism to determination of carrier status in Glanzmann's thrombasthenia families of Chinese origin. <i>Thromb Haemost 1993 Jan 11;69:64-9</i> [PMID 8095357] </p> <p> <b>Charbonnier, 1998 : </b> Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard LComparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. <i>Thromb Haemost 1998;79:897-901</i> [PMID 9609216] </p> <p> <b>Holmstr�m, 1992 : </b> Holmostr�m M, Berglund MC, Granquist S, Bratt G, T�rnebohm E, Lockner DFragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. <i>Thromb Res 1992;67:49-55</i> [PMID 1332213] </p> <p> <b>Merli, 2001 : </b> Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska KSubcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. <i>Ann Intern Med 2001;134:191-202</i> [PMID 11177331] </p> <p> <b>Partsch, 1996 : </b> Partsch H, Kechavarz B, Mostbeck A, K�hn H, Lipp CFrequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. <i>J Vasc Surg 1996;24:774-82</i> [PMID 8918323] </p> <p> <b>Siegbahn, 1989 : </b> Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, Hedner USubcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. <i>Thromb Res 1989;55:767-78</i> [PMID 2551070] </p> <p> <b>O�Sullivan 1972, : </b> O'Sullivan EFDuration of anticoagulant therapy in venous thrombo--embolism. <i>Med J Aust 1972;2:1104-7</i> [PMID 4640564] </p> <p> <b>Holmgren 1985, : </b> Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist SOne-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. <i>Acta Med Scand 1985;218:279-84</i> [PMID 3907286] </p> <p> <b>Schulman 3 vs 1.5 1985, : </b> Schulman S, Lockner D, Juhlin-Dannfelt AThe duration of oral anticoagulation after deep vein thrombosis. A randomized study. <i>Acta Med Scand 1985;217:547-52</i> [PMID 3895828] </p> <p> <b>Schulman 6 vs 3 1985, : </b> Schulman S, Lockner D, Juhlin-Dannfelt AThe duration of oral anticoagulation after deep vein thrombosis. A randomized study. <i>Acta Med Scand 1985;217:547-52</i> [PMID 3895828] </p> <p> <b>Fennerty 1987, : </b> Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PAA comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. <i>Clin Lab Haematol 1987;9:17-21</i> [PMID 3581712] </p> <p> <b>British Thoracic Society 1992, : </b> Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. <i>Lancet 1992;340:873-6</i> [PMID 1357297] </p> <p> <b>Belcaro 1993, : </b> Belcaro G, Errichi BM, De Simone PPrevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. <i>Angiology 1993;44:328-31</i> [PMID 8457085] </p> <p> <b>Levine, 1995 : </b> Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers POptimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. <i>Thromb Haemost 1995;74:606-11</i> [PMID 8584992] </p> <p> <b>Schulman, 1995 : </b> Schulman S, Rhedin AS, Lindmarker P, Carlsson A, L�rfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter HA comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. <i>N Engl J Med 1995;332:1661-5</i> [PMID 7760866] </p> <p> <b>Kearon, 1999 : </b> Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JAA comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>N Engl J Med 1999;340:901-7</i> [PMID 10089183] </p> <p> <b>Agnelli, 2001 : </b> Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno WThree months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. <i>N Engl J Med 2001;345:165-9</i> [PMID 11463010] </p> <p> <b>Pinede, 2001 : </b> Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JPComparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. <i>Circulation 2001;103:2453-60</i> [PMID 11369685] </p> <p> <b>Agnelli, 2003 : </b> Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin PExtended oral anticoagulant therapy after a first episode of pulmonary embolism. <i>Ann Intern Med 2003;139:19-25</i> [PMID 12834314] </p> <p> <b>Ridker 2003, : </b> Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJLong-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. <i>N Engl J Med 2003;348:1425-34</i> [PMID 12601075] </p> <p> <b>Schulman 2003, : </b> Schulman S, W�hlander K, Lundstr�m T, Clason SB, Eriksson HSecondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. <i>N Engl J Med 2003;349:1713-21</i> [PMID 14585939] </p> <p> <b>Kearon, 2004 : </b> Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent MComparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. <i>J Thromb Haemost 2004;2:743-9</i> [PMID 15099280] </p> <p> <b>Boccalon, 2000 : </b> Boccalon H, Elias A, Chal� JJ, Cad�ne A, Gabriel SClinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. <i>Arch Intern Med 2000;160:1769-73</i> [PMID 10871969] </p> <p> <b>Chong, 2005 : </b> Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CHOnce-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. <i>J Thromb Thrombolysis 2005;19:173-81</i> [PMID 16082604] </p> <p> <b>Daskalopoulos, 2005 : </b> Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, Kakissis I, Liapis CDLong-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. <i>Eur J Vasc Endovasc Surg 2005;29:638-50</i> [PMID 15878544] </p> <p> <b>Koopman, 1996 : </b> Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MHTreatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. <i>N Engl J Med 1996;334:682-7</i> [PMID 8594426] </p> <p> <b>Koopman, 1996 : </b> van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, B�ller HRReplacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group. <i>Thromb Haemost 1998;79:259-63</i> [PMID 9493572] </p> <p> <b>Levine, 1996 : </b> Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs MA comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. <i>N Engl J Med 1996;334:677-81</i> [PMID 8594425] </p> <p> <b>Levine, 1996 : </b> O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent MEconomic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. <i>Arch Intern Med 1999;159:2298-304</i> [PMID 10547169] </p> <p> <b>Ramacciotti, 2004 : </b> Ramacciotti E, Ara�jo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto FAn open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. <i>Thromb Res 2004;114:149-53</i> [PMID 15342210] </p> <p> <b>Merli (once daily vs UFH), 2001 : </b> Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska KSubcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. <i>Ann Intern Med 2001 Feb 6;134:191-202</i> [PMID 11177331] </p> <p> <b>Merli, 2001 : </b> Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska KSubcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. <i>Ann Intern Med 2001 Feb 6;134:191-202</i> [PMID 11177331] </p> <p> <b>Schulman, 1997 : </b> Schulman S, Granqvist S, Holmstr�m M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, L�rfars G, Leijd B, Linder O, Loogna EThe duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. <i>N Engl J Med 1997;336:393-8</i> [PMID 9010144] </p> <p> <b>MATISSE, 2004 : </b> B�ller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AWFondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. <i>Ann Intern Med 2004;140:867-73</i> [PMID 15172900] </p> <p> <b>THRIVE I, 0 : </b> Eriksson H, W�hlander K, Gustafsson D, Welin LT, Frison L, Schulman SA randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. <i>J Thromb Haemost 2003 Jan;1:41-7</i> [PMID 12871538] </p> <p> <b>Ott import�, 1998 : </b> Ott P, Eldrup E, Oxholm P[Value of anticoagulant therapy in deep venous thrombosis in the lower limb in elderly, mobilized patients. A double-blind placebo controlled study with open therapeutic guidance] <i>Ugeskr Laeger 1988;150:218-21</i> [PMID 3287734] </p> <p> <b>Nielsen import�, 1994 : </b> Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen HHSilent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. <i>J Intern Med 1994;235:457-61</i> [PMID 8182402] </p> <p> <b>Nielsen import�, 1994 : </b> Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen HH, Nielsen BO, Petersen JB, Bechgaard PAnticoagulant therapy in deep venous thrombosis. A randomized controlled study. <i>Thromb Res 1994;73:215-26</i> [PMID 8191414] </p> <p> <b>Fiessinger , 2005 : </b> Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstr�m T, Berkowitz SD, Nystr�m P, Thors�n M, Ginsberg JSXimelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. <i>JAMA 2005 Feb 9;293:681-9</i> [PMID 15701909] </p> <p> <b>Krahenbuhl, 1979 : </b> Kr�henb�hl B, Simon CA, Bouvier CA, Schinas P, Hopf MA, Cochet B[Heparin treatment. Comparison between intravenous and subcutaneous administration] <i>Schweiz Med Wochenschr 1979;109:1322-5</i> [PMID 504973] </p> <p> <b>Bentley, 1980 : </b> Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones NAn objective study of alternative methods of heparin administration. <i>Thromb Res 1980;18:177-87</i> [PMID 7404497] </p> <p> <b>Andersson, 1982 : </b> Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist SSubcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. <i>Thromb Res 1982;27:631-9</i> [PMID 7179208] </p> <p> <b>Hull, 1986 : </b> Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison LContinuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. <i>N Engl J Med 1986;315:1109-14</i> [PMID 3531862] </p> <p> <b>Doyle, 1987 : </b> Doyle DJ, Turpie AG, Hirsh J, Best C, Kinch D, Levine MN, Gent MAdjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. <i>Ann Intern Med 1987;107:441-5</i> [PMID 3307582] </p> <p> <b>Walker, 1987 : </b> Walker MG, Shaw JW, Thomson GJ, Cumming JG, Thomas MLSubcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. <i>Br Med J (Clin Res Ed) 1987;294:1189-92</i> [PMID 3109574] </p> <p> <b>Pini, 1990 : </b> Pini M, Pattachini C, Quintavalla R, Poli T, Megha A, Tagliaferri A, Manotti C, Dettori AGSubcutaneous vs intravenous heparin in the treatment of deep venous thrombosis--a randomized clinical trial. <i>Thromb Haemost 1990;64:222-6</i> [PMID 2270531] </p> <p> <b>Pini, 1994 : </b> Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AGLow molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. <i>Thromb Haemost 1994;72:191-7</i> [PMID 7831650] </p> <p> <b>Das, 1996 : </b> Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VVLow-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. <i>World J Surg 1996;20:521-6; discussion 526-7</i> [PMID 8661630] </p> <p> <b>Gonzalez-Fajardo, 1999 : </b> Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Guti�rrez V, Vaquero CVenographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. <i>J Vasc Surg 1999;30:283-92</i> [PMID 10436448] </p> <p> <b>Gonzalez-Fajardo, 1999 : </b> Gonz�lez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta CEffect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. <i>J Vasc Surg 2008 Oct;48:953-9</i> [PMID 18639417] </p> <p> <b>Lopaciuk, 1999 : </b> Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora ALow molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. <i>Thromb Haemost 1999;81:26-31</i> [PMID 9974369] </p> <p> <b>Veiga, 2000 : </b> Veiga F, Escrib� A, Maluenda MP, L�pez Rubio M, Margalet I, Lezana A, Gallego J, Ribera JMLow molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. <i>Thromb Haemost 2000;84:559-64</i> [PMID 11057850] </p> <p> <b>Lopez-Beret, 2001 : </b> L�pez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, Romero ALow molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. <i>J Vasc Surg 2001;33:77-90</i> [PMID 11137927] </p> <p> <b>Meyer, 2002 : </b> Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge DComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. <i>Arch Intern Med 2002;162:1729-35</i> [PMID 12153376] </p> <p> <b>Hull, 2002 : </b> Hull RD, Pineo GF, Mah AF, et al, for the LITE StudyA randomized trial evaluating long-term lowmolecular- weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract].582258 <i>Blood 2002; 100:148a</i> [PMID ] </p> <p> <b>Deitcher, 2003 : </b> Deitcher SR, Kessler MG, Lyons RM., imagTreatment of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period [abstract].s-e <i>Blood 2003; 102:322a</i> [PMID ] </p> <p> <b>Kakkar, 2003 : </b> Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco PLow-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. <i>Thromb Haemost 2003;89:674-80</i> [PMID 12669122] </p> <p> <b>Lee, 2003 : </b> Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent MLow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <i>N Engl J Med 2003;349:146-53</i> [PMID 12853587] </p> <p> <b>Lee, 2003 : </b> Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MNRandomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. <i>J Clin Oncol 2005;23:2123-9</i> [PMID 15699480] </p> <p> <b>Einstein-DVT Dose-Ranging Study, 2008 : </b> Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers AA dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. <i>Blood 2008;112:2242-7</i> [PMID 18621928] </p> <p> <b>Botticelli DVT, 2008 : </b> Buller H, Deitchman D, Prins M, Segers AEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. <i>J Thromb Haemost 2008 Aug;6:1313-8</i> [PMID 18541000] </p> <p> <b>Gonz�lez-Fajardo, 2008 : </b> Gonz�lez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta CEffect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. <i>J Vasc Surg 2008;48:953-9</i> [PMID 18639417] </p> <p> <b>VanGogh DVT, 2007 : </b> Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE <i>N Engl J Med 2007 Sep 13;357:1094-104</i> [PMID 17855670] </p> <p> <b>VanGogh extension, 2007 : </b> Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE <i>N Engl J Med 2007 Sep 13;357:1105-12</i> [PMID 17855671] 10.1056/NEJMoa067703 </p> <p> <b>Romera, 2009 : </b> Romera A, Cairols MA, Vila-Coll R, Mart� X, Colom� E, Bonell A, Lapiedra OA randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. <i>Eur J Vasc Endovasc Surg 2009;37:349-56</i> [PMID 19121589] </p> <p> <b>RE-COVER, 2009 : </b> Schulman S, Eriksson H, Goldhaber SZ, et al. Dabigatran etexilate versus warfarin in the treatment of venous thromboembolism. Oral presentation, <i>ASH Annual Meeting 2009, Abstract number 19394, 6 December 2009 </i> [PMID ] </p> <p> <b>RE-COVER, 2009 : </b> Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZDabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>N Engl J Med 2009 Dec 10;361:2342-52</i> [PMID 19966341] 10.1056/NEJMoa0906598 </p> <p> <b>VanGogh PE, 2007 : </b> Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE <i>N Engl J Med 2007 Sep 13;357:1094-104</i> [PMID 17855670] </p> <p> <b>MATISSE PE, 2003 : </b> B�ller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AWSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. <i>N Engl J Med 2003 Oct 30;349:1695-702</i> [PMID 14585937] </p>